Sitagliptin/metformin
Sitagliptin/metformin, sold under the brand name Janumet among others, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes.[2] It may be used in those whose blood sugar is not controlled with metformin and a sulfonylurea.[2][3] It is taken by mouth.[2]
Combination of | |
---|---|
Sitagliptin | Dipeptidyl peptidase-4 inhibitor |
Metformin | Biguanide |
Clinical data | |
Trade names | Janumet, Januet, others |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
DrugBank | |
UNII | |
KEGG |
Common side effects include diarrhea, headache, and upper respiratory tract infections.[1] Serious side effects may include lactic acidosis, pancreatitis, low blood sugar, heart failure, joint pain, and allergic reactions.[1] It has not been properly studied in people who are pregnant or breastfeeding.[4] It contains sitagliptin (a dipeptidyl peptidase-4 inhibitor) and metformin (a biguanide).[1]
The combination was approved for medical use in the United States in 2007.[1] In 2017, it was the 139th most commonly prescribed medication in the United States, with more than four million prescriptions.[5][6]
Society and culture
Brand names
As of 2018, the combination was marketed under several brand names, including Efficib, Janmet, Januet, Janumet, Jznumet, Ristaben Met, Ristfor, Siglimet, Sitamet, Sitar-M, Sliptin-M, Treviamet, and Velmetia.[7]
Price
A month supply in the United Kingdom costs the NHS about 33.26 £ as of 2019.[2] In the United States the wholesale cost of this amount is about US$433.[8] In Denmark 100 tablets (each 1,000 mg) cost over the counter in a pharmacy DKK 62.60 = US$9.40 = £7.50, thus a month supply in Denmark costs DKK 37.50 = US$5.70 = £4.50. The pharmacy buys wholesale at DKK 33.83 = US$5.11 = £4.10.[9]
References
- "Janumet - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 19 April 2019.
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 682. ISBN 9780857113382.
- Hayes J, Anderson R, Stephens JW (2016). "Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy". Drug Design, Development and Therapy. 10: 2263–70. doi:10.2147/DDDT.S93076. PMC 4958358. PMID 27486305.
- "Metformin / sitagliptin Use During Pregnancy". Drugs.com. Retrieved 19 April 2019.
- "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- "Metformin Hydrochloride; Sitagliptin Phosphate - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- "International brands for Sitagliptin/metformin". Drugs.com. Retrieved 3 September 2018.
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- "Medicinpriser". Medicinpriser (in Danish). Retrieved 17 June 2019.
External links
- "Sitagliptin". Drug Information Portal. U.S. National Library of Medicine.
- "Metformin". Drug Information Portal. U.S. National Library of Medicine.